Department of Cardiothoracic Surgery, Great Ormond Street Hospital, London, UK.
Cardiovasc Ther. 2010 Oct;28(5):e65-71. doi: 10.1111/j.1755-5922.2010.00158.x.
The last decade has seen major advances in the pharmacotherapy of pulmonary arterial hypertension (PAH). One of these advances has been the discovery of endothelin receptor antagonists (ERAs). ERAs are a class of potent vasodilators and antimitotic substances, which could specifically dilate and remodel pulmonary arterial system, and have been proposed as an alternative to traditional therapies for PAH. Current available evidence suggests that ERAs improve exercise capacity, functional status, pulmonary hemodynamics, and delay the time to clinical worsening for patients with PAH. This review attempts to provide an overview of the pharmacology, therapeutic benefits, and safety profile of ERAs in patients with PAH.
在过去的十年中，肺动脉高压（PAH）的药物治疗取得了重大进展。其中一项进展是发现了内皮素受体拮抗剂（ERAs）。ERAs 是一类强效的血管扩张剂和抗有丝分裂物质，可特异性扩张和重塑肺动脉系统，被提议作为 PAH 传统治疗方法的替代方法。目前的证据表明，ERAs 可改善 PAH 患者的运动能力、功能状态、肺血流动力学，并延迟临床恶化的时间。本综述试图概述 ERAs 在 PAH 患者中的药理学、治疗益处和安全性特征。
